BioXcel Therapeutics, Inc. Paid-in-Kind Interest
BioXcel Therapeutics, Inc. (BTAI) reported Paid-in-Kind Interest of $3.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-13
- BioXcel Therapeutics, Inc. paid-in-kind interest for the quarter ending 2026-06-30 was $3.41M, a 23.29% increase year-over-year.
- BioXcel Therapeutics, Inc. paid-in-kind interest for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. paid-in-kind interest for the quarter ending 2025-09-30 was $1.00K, a 99.92% decline year-over-year.
- BioXcel Therapeutics, Inc. paid-in-kind interest for fiscal 2025 was $5.43M, a 16.95% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. paid-in-kind interest for fiscal 2024 was $6.54M, a 249.52% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. paid-in-kind interest for fiscal 2023 was $1.87M, a 131.97% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. paid-in-kind interest for fiscal 2022 was $807.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.41M 10-Q · filed 2026-08-13 | $3.41M derived: sum of 3 quarters · filed 2026-08-13 | $3.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $1.00K derived: sum of 3 quarters · filed 2026-05-15 | $2.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $1.00K derived: sum of 2 quarters · filed 2026-03-27 | $2.77M derived: sum of 3 quarters · filed 2026-08-13 | $5.43M 10-K · filed 2026-03-27 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.77M derived: sum of 2 quarters · filed 2026-08-13 | $5.43M 10-Q · filed 2025-11-12 | $8.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.43M 10-Q · filed 2026-08-13 | $8.15M derived: sum of 3 quarters · filed 2026-08-13 | $9.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.67M 10-Q · filed 2026-05-15 | $5.39M derived: sum of 2 quarters · filed 2026-05-15 | $6.72M derived: sum of 3 quarters · filed 2026-05-15 | $8.00M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.05M derived: sum of 2 quarters · filed 2026-03-27 | $5.33M derived: sum of 3 quarters · filed 2026-03-27 | $6.54M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.60M derived: sum of 2 quarters · filed 2025-11-12 | $3.82M 10-Q · filed 2025-11-12 | $4.48M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.49M 10-Q · filed 2025-08-12 | $3.15M derived: sum of 3 quarters · filed 2025-08-12 | $3.56M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.22M 10-Q · filed 2025-05-12 | $1.87M derived: sum of 2 quarters · filed 2025-05-12 | $2.29M derived: sum of 3 quarters · filed 2025-05-12 | $2.69M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $657.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $1.07M derived: sum of 2 quarters · filed 2025-03-28 | $1.47M derived: sum of 3 quarters · filed 2025-03-28 | $1.87M 10-K · filed 2025-03-28 |
| 2023-09-30 | $412.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $817.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.22M 10-Q · filed 2024-11-14 | $1.62M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $405.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $803.00K 10-Q · filed 2024-08-06 | $1.21M derived: sum of 3 quarters · filed 2024-08-06 | |
| 2023-03-31 | $398.00K 10-Q · filed 2024-05-09 | $802.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $404.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $807.00K 10-K · filed 2024-03-22 | ||
| 2022-09-30 | $403.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |